128 related articles for article (PubMed ID: 11677852)
1. [Biological markers: utilization in drug development and approval].
Gueyffier F; Dib M; Boissel JP
Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
[TBL] [Abstract][Full Text] [Related]
2. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of clinical efficacy.
Michelson S; Sehgal A; Friedrich C
Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
[TBL] [Abstract][Full Text] [Related]
4. Using imaging biomarkers to accelerate drug development and clinical trials.
Pien HH; Fischman AJ; Thrall JH; Sorensen AG
Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Carroll KJ
Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
[TBL] [Abstract][Full Text] [Related]
6. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
8. Drug markers questioned.
Ledford H
Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
[No Abstract] [Full Text] [Related]
9. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.
Lee JW; Hall M
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1259-71. PubMed ID: 19038585
[TBL] [Abstract][Full Text] [Related]
10. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
Lassere MN
Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
[TBL] [Abstract][Full Text] [Related]
11. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
12. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
Muller PY; Dieterle F
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
[TBL] [Abstract][Full Text] [Related]
13. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
Wang SJ
Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
Disse B
Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for TB treatment response: challenges and future strategies.
Walzl G; Ronacher K; Djoba Siawaya JF; Dockrell HM
J Infect; 2008 Aug; 57(2):103-9. PubMed ID: 18649943
[TBL] [Abstract][Full Text] [Related]
16. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
[TBL] [Abstract][Full Text] [Related]
17. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
Giacoia GP; Mattison DR
Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
[TBL] [Abstract][Full Text] [Related]
18. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.
Wagner JA; Williams SA; Webster CJ
Clin Pharmacol Ther; 2007 Jan; 81(1):104-7. PubMed ID: 17186007
[TBL] [Abstract][Full Text] [Related]
20. Using disease progression models as a tool to detect drug effect.
Mould DR; Denman NG; Duffull S
Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
